ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,881.63
      -0.43%
      US Tech 100
      20,449.60
      -0.85%
      Dow Jones
      42,544.22
      -0.07%
      Brent Oil
      73.855
      -1.33%
      Bitcoin
      94,038.85
      0.70%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Recursion Pharmaceuticals Inc (RXRX) Quote

      Recursion Pharmaceuticals Inc

      Recursion Pharmaceuticals Inc (RXRX)

      NASDAQ
      6.76
      -0.01
      (-0.15%)
      Closed January 01 4:00PM
      Delayed by 15 minutes
      6.79
      0.03
      (0.44%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      6.79
      Bid
      6.79
      Ask
      6.81
      Volume
      12,109,938
      6.65 Day's Range 7.20
      5.61 52 Week Range 15.74
      Market Cap
      1.946B
      Previous Close
      6.77
      Open
      6.83
      Last Trade
      3500
      @
      6.79
      (formt)
      Last Trade Time
      Financial Volume
      $ 82,834,456
      VWAP
      6.8402
      Average Volume (3m)
      10,241,127
      Shares Outstanding
      286,640,833
      Dividend Yield
      -
      PE Ratio
      -5.90
      Earnings Per Share (EPS)
      -1.14
      Revenue
      44.58M
      Net Profit
      -328.07M

      About Recursion Pharmaceuticals Inc

      Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery... Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.recursion.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Recursion Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RXRX. The last closing price for Recursion Pharmaceuticals was $6.77. Over the last year, Recursion Pharmaceuticals shares have traded in a share price range of $ 5.61 to $ 15.74.

      Recursion Pharmaceuticals currently has 286,640,833 shares outstanding. The market capitalization of Recursion Pharmaceuticals is $1.94 billion. Recursion Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.90.

      Ask ADVFN Intelligence (AI)

      Recursion Pharmaceuticals (RXRX) Options Flow Summary

      RXRX Options Flow

      Overall Flow

      Bullish

      Net Premium

      130k

      Calls / Puts

      300.00%

      Buys / Sells

      0.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      RXRX Latest News

      More News

      Form 144 - Report of proposed sale of securities

      December 26 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 20 2024
      Edgar (US Regulatory)

      Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

      Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize...

      December 20 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 18 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 17 2024
      Edgar (US Regulatory)

      Form 424B7 - Prospectus [Rule 424(b)(7)]

      December 17 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 11 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      December 10 2024
      Edgar (US Regulatory)

      Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

      REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target...

      December 09 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      December 06 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.45-6.215469613267.247.866.72143436707.30067829CS
      4-0.65-8.736559139787.449.555.93165258717.19373214CS
      120.619.870550161816.189.555.61102411276.91279382CS
      26-0.74-9.827357237727.539.555.6173898126.9633574CS
      52-2.86-29.63730569959.6515.745.6168091898.50486253CS
      156-10.7-61.177815894817.4918.234.5438123468.86617103CS
      260-23.21-77.36666666673042.814.5432436479.58797331CS

      RXRX - Frequently Asked Questions (FAQ)

      What is the current Recursion Pharmaceuticals share price?
      The current share price of Recursion Pharmaceuticals is $ 6.79
      How many Recursion Pharmaceuticals shares are in issue?
      Recursion Pharmaceuticals has 286,640,833 shares in issue
      What is the market cap of Recursion Pharmaceuticals?
      The market capitalisation of Recursion Pharmaceuticals is USD 1.94B
      What is the 1 year trading range for Recursion Pharmaceuticals share price?
      Recursion Pharmaceuticals has traded in the range of $ 5.61 to $ 15.74 during the past year
      What is the PE ratio of Recursion Pharmaceuticals?
      The price to earnings ratio of Recursion Pharmaceuticals is -5.9
      What is the cash to sales ratio of Recursion Pharmaceuticals?
      The cash to sales ratio of Recursion Pharmaceuticals is 43.41
      What is the reporting currency for Recursion Pharmaceuticals?
      Recursion Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for Recursion Pharmaceuticals?
      The latest annual turnover of Recursion Pharmaceuticals is USD 44.58M
      What is the latest annual profit for Recursion Pharmaceuticals?
      The latest annual profit of Recursion Pharmaceuticals is USD -328.07M
      What is the registered address of Recursion Pharmaceuticals?
      The registered address for Recursion Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Recursion Pharmaceuticals website address?
      The website address for Recursion Pharmaceuticals is www.recursion.com
      Which industry sector does Recursion Pharmaceuticals operate in?
      Recursion Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BDMDBaird Medical Investment Holdings Ltd
      $ 7.6699
      (630.47%)
      		89.74M
      APMAptorum Group Ltd
      $ 2.799
      (106.57%)
      		116.74M
      COEPCoeptis Therapeutics Holdings Inc
      $ 5.44
      (75.48%)
      		5.08M
      VRMEVerifyMe Inc
      $ 1.332
      (68.63%)
      		94.04M
      VEEETwin Vee PowerCats Company
      $ 0.55
      (53.59%)
      		5.62M
      WATTEnergous Corporation
      $ 1.00
      (-62.26%)
      		29.33M
      SGMOSangamo Therapeutics Inc
      $ 1.02
      (-56.41%)
      		44.56M
      INTZIntrusion Inc
      $ 3.07
      (-45.95%)
      		15.07M
      KZIAKazia Therapeutics Ltd
      $ 1.78
      (-42.58%)
      		708.99k
      TOIIWOncology Institute Inc
      $ 0.0052
      (-42.22%)
      		366.02k
      SVMHSRIVARU Holding Ltd
      $ 0.0423
      (26.65%)
      		794.74M
      XTIAXTI Aerospace Inc
      $ 0.0422
      (6.84%)
      		446.31M
      EYENEyenovia Inc
      $ 0.1474
      (30.10%)
      		412.83M
      CRKNCrown Electrokinetics Corporation
      $ 0.146899
      (5.91%)
      		402.05M
      ONCOOnconetix Inc
      $ 0.6479
      (48.26%)
      		270.47M

      RXRX Discussion

      View Posts
      bwrbad bwrbad 1 day ago
      balding haircut at RXRX
      👍️0
      Monksdream Monksdream 1 week ago
      RXRX, under $7
      👍️0
      bwrbad bwrbad 2 weeks ago
      out for now, let CEO work his magic if he has one under his sleeve
      👍️0
      bwrbad bwrbad 2 weeks ago
      is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
      what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
      👍️0
      bwrbad bwrbad 2 weeks ago
      RXRX
      👍️0
      bwrbad bwrbad 2 weeks ago
      RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
      👍️0
      bwrbad bwrbad 3 weeks ago
      RxRx M&A: Valence –Cyclica - Exscientia
      Valence – a leader in generative AI and deep learning models
      Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
      Exscientia - AI-driven precision medicine
      RXRX - Regenerative AI - TechBio powerhouse
      undergoing post merger reorganization, some job cuts
      enough cash to fund through 2027
      Ark Q3 2024 Stake: $215.9 million
      Hedge Fund Investors Q3 2024:: 16
      more than ten drugs in trials.
      👍️0
      bwrbad bwrbad 3 weeks ago
      market up big and RxRx ignored,
      if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
      👍️0
      TucsonPhil TucsonPhil 3 weeks ago
      RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

      If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
      👍️ 1
      bwrbad bwrbad 3 weeks ago
      Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
      Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
      Shares Outstanding 6 388.94M; Float 8 252.42M
      clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

      % Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
      👍️ 1
      JJ8 JJ8 3 weeks ago
      Rxrx share price Long Tail Up since 06 Dec 2024.
      👍️0
      paperman paperman 3 weeks ago
      Phase 1 news expected tonight at conference.
      👍️0
      paperman paperman 3 weeks ago
      Phase 1 news expected tonight at conference.
      👍️0
      bwrbad bwrbad 3 weeks ago
      this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...
      👍️0
      JJ8 JJ8 4 weeks ago
      Bought it yesterday at $6.60

      Today it's up about 22%.

      Same story with 2 other stocks and they all go up today more than 20%!

      Whoa! IN CREDIBLE!
      👍️0
      TucsonPhil TucsonPhil 4 weeks ago
      Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.
      👍️0
      bwrbad bwrbad 4 weeks ago
      RxRx going to be top player in future pharma drug discovery
      👍️0
      TucsonPhil TucsonPhil 4 weeks ago
      Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.
      👍️0
      bwrbad bwrbad 4 weeks ago
      GOOG -- RxRx -- NVDA -- RxRx -- MSFT
      👍️0
      bwrbad bwrbad 4 weeks ago
      agree but better, much bigger scope, on way to become a high flying company of the future
      price target 150 in two year
      👍️0
      uksausage uksausage 4 weeks ago
      no it is the PLTR of Drug discovery
      both rely on NVDA to run fast
      👍️0
      bwrbad bwrbad 4 weeks ago
      started buying little little- this is NVDA of DRUG DISCOVERY
      👍️0
      ToucanYoucan ToucanYoucan 4 weeks ago
      $RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.
      👍️0
      bwrbad bwrbad 4 weeks ago
      high potential if delivers,
      👍️0
      TucsonPhil TucsonPhil 4 weeks ago
      Good gains in past week, but looks like it is getting ready to drift lower again.
      👍️0
      TucsonPhil TucsonPhil 4 weeks ago
      First patient dosed.

      https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study
      👍️0
      lambchops lambchops 1 month ago
      Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

      LC

      RXRX
      👍️ 1
      ToucanYoucan ToucanYoucan 1 month ago
      $RXRX - Having a huge day here!!
      👍️0
      ToucanYoucan ToucanYoucan 1 month ago
      $RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo
      👍️0
      TucsonPhil TucsonPhil 2 months ago
      Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

      Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.
      👍️0
      Monksdream Monksdream 2 months ago
      RXRX 10Q 11/6
      👍️0
      Monksdream Monksdream 2 months ago
      RXRX under $10
      👍️0
      Monksdream Monksdream 2 months ago
      RXRX under $10
      👍️0
      mick mick 2 months ago
      👍️0
      abrooklyn abrooklyn 3 months ago
      https://x.com/RecursionPharma/status/1841453309342740925
      👍️0
      TucsonPhil TucsonPhil 3 months ago
      So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

      https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

      https://www.recursion.com/pipeline
      👍️0
      mick mick 3 months ago
      WALL @ $7.5 , $7.0
      👍️0
      mick mick 3 months ago
      https://www.stockscores.com/charts/charts/?ticker=RXRX
      👍️0
      lambchops lambchops 4 months ago
      Yes. Good stock to put on watchlist IMO.
      Still reasonably cheap. Check MACD.

      LC

      RXRX
      👍️0
      mick mick 4 months ago
      diamond in the ruff

      RXRX
      Recursion Pharmaceuticals Inc
      6.32
      0.20 (3.27%)
      Volume: 3,082,418
      Day Range: 6.055 - 6.32
      Last Trade Time: 4:28:47 PM EDT
      👍️0
      mick mick 4 months ago
      RXRX
      Recursion Pharmaceuticals Inc
      5.95
      -0.22 (-3.57%)
      Volume: 4,577,882
      Day Range: 5.895 - 6.30
      Last Trade Time: 7:58:59 PM EDT
      👍️0
      lambchops lambchops 4 months ago
      Yes, I've been adding shares of RXRX this week.

      LC

      RXRX
      👍️0
      TucsonPhil TucsonPhil 4 months ago
      Looks.like a little dilution, but a good buying opportunity, to add some more.
      👍️0
      lambchops lambchops 4 months ago
      Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
      Please note I own shares in this company.

      LC

      RXRX
      👍️0
      TucsonPhil TucsonPhil 4 months ago
      I had not seen that merger announcement. Never came across in my broker news feed.
      👍️0
      lambchops lambchops 4 months ago
      Did you see the possible merger news?

      LC

      RXRX
      👍️0
      TucsonPhil TucsonPhil 4 months ago
      Running millions of tests per week, to find promising drug candidates.

      What we do not know, is how many candidates have entered clinical trials.

      When news pops about RXRX origination of promising cures, this will skyrocket.

      Oops, missed this one:

      https://ir.recursion.com/news-releases/news-release-details/recursion-announces-phase-2-data-rec-994-first-disease
      👍️0
      lambchops lambchops 4 months ago
      Looks ready to move IMO.

      LC

      RXRX
      👍️0
      TucsonPhil TucsonPhil 4 months ago
      Looking for a move into the 9.25-9.50 range within the next few weeks.
      👍️0
      lambchops lambchops 4 months ago
      RXRX looks ready for another move upward.
      👍️0

      Your Recent History

      NASDAQ
      RXRX
      Recursion Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads